Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants

Alyson Calder, Graham T. Bell, Martin Andersson, Alison H. Thomson, David G. Watson, Neil S. Morton

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentrationtime profiles and to determine the efficacy and adverse event profile of the epidural regimen. Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.5 mg kg(-1) bupivacaine (0.25%) or ropivacaine (0.2%) followed 2 h later by an infusion of 0.2 mg kg(-1) h(-1) in those undergoing abdominal surgery. Total and unbound concentrations of bupivacaine and ropivacaine were analyzed using NONMEM. Hourly pain scores and adverse effects were recorded. Results: Bupivacaine data were available from 11 infants (five had infusions) and ropivacaine from 13 infants (four had infusions). Alpha-1-acid glycoprotein and total bupivacaine and ropivacaine concentrations accumulated during infusions, but unbound concentrations did not. Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg l(-1) (bupivacaine) and 0.13 mg l(-1) (ropivacaine). Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l h(-1) kg) 1 and of total (unbound) ropivacaine were 0.288 (3.31) l h(-1) kg(-1). Pain scores requiring pain team referral occurred once with bupivacaine and four times with ropivacaine. No toxicity was observed. Epidural infusions of 0.2 mg(-1) kg(-1) h(-1) bupivacaine or ropivacaine appeared to be well tolerated and efficacious in this population. No accumulation of unbound drug concentrations occurred.

LanguageEnglish
Pages430-437
Number of pages8
JournalPediatric Anesthesia
Volume22
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Bupivacaine
Pharmacokinetics
Orosomucoid
Pain
ropivacaine
Epidural Injections
Herniorrhaphy
Biological Availability
Referral and Consultation
Newborn Infant

Keywords

  • epidural bupivacaine
  • ropivacaine
  • young infants
  • pharmacokinetic profiles

Cite this

@article{bc431a19767b413b82bd30f3ef04a8fd,
title = "Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants",
abstract = "The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentrationtime profiles and to determine the efficacy and adverse event profile of the epidural regimen. Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.5 mg kg(-1) bupivacaine (0.25{\%}) or ropivacaine (0.2{\%}) followed 2 h later by an infusion of 0.2 mg kg(-1) h(-1) in those undergoing abdominal surgery. Total and unbound concentrations of bupivacaine and ropivacaine were analyzed using NONMEM. Hourly pain scores and adverse effects were recorded. Results: Bupivacaine data were available from 11 infants (five had infusions) and ropivacaine from 13 infants (four had infusions). Alpha-1-acid glycoprotein and total bupivacaine and ropivacaine concentrations accumulated during infusions, but unbound concentrations did not. Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg l(-1) (bupivacaine) and 0.13 mg l(-1) (ropivacaine). Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l h(-1) kg) 1 and of total (unbound) ropivacaine were 0.288 (3.31) l h(-1) kg(-1). Pain scores requiring pain team referral occurred once with bupivacaine and four times with ropivacaine. No toxicity was observed. Epidural infusions of 0.2 mg(-1) kg(-1) h(-1) bupivacaine or ropivacaine appeared to be well tolerated and efficacious in this population. No accumulation of unbound drug concentrations occurred.",
keywords = "epidural bupivacaine , ropivacaine , young infants , pharmacokinetic profiles",
author = "Alyson Calder and Bell, {Graham T.} and Martin Andersson and Thomson, {Alison H.} and Watson, {David G.} and Morton, {Neil S.}",
year = "2012",
month = "5",
doi = "10.1111/j.1460-9592.2011.03771.x",
language = "English",
volume = "22",
pages = "430--437",
journal = "Pediatric Anesthesia",
issn = "1155-5645",
number = "5",

}

Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. / Calder, Alyson; Bell, Graham T.; Andersson, Martin; Thomson, Alison H.; Watson, David G.; Morton, Neil S.

In: Pediatric Anesthesia, Vol. 22, No. 5, 05.2012, p. 430-437.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants

AU - Calder, Alyson

AU - Bell, Graham T.

AU - Andersson, Martin

AU - Thomson, Alison H.

AU - Watson, David G.

AU - Morton, Neil S.

PY - 2012/5

Y1 - 2012/5

N2 - The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentrationtime profiles and to determine the efficacy and adverse event profile of the epidural regimen. Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.5 mg kg(-1) bupivacaine (0.25%) or ropivacaine (0.2%) followed 2 h later by an infusion of 0.2 mg kg(-1) h(-1) in those undergoing abdominal surgery. Total and unbound concentrations of bupivacaine and ropivacaine were analyzed using NONMEM. Hourly pain scores and adverse effects were recorded. Results: Bupivacaine data were available from 11 infants (five had infusions) and ropivacaine from 13 infants (four had infusions). Alpha-1-acid glycoprotein and total bupivacaine and ropivacaine concentrations accumulated during infusions, but unbound concentrations did not. Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg l(-1) (bupivacaine) and 0.13 mg l(-1) (ropivacaine). Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l h(-1) kg) 1 and of total (unbound) ropivacaine were 0.288 (3.31) l h(-1) kg(-1). Pain scores requiring pain team referral occurred once with bupivacaine and four times with ropivacaine. No toxicity was observed. Epidural infusions of 0.2 mg(-1) kg(-1) h(-1) bupivacaine or ropivacaine appeared to be well tolerated and efficacious in this population. No accumulation of unbound drug concentrations occurred.

AB - The primary aim of this study was to describe the pharmacokinetics of total and unbound bupivacaine and ropivacaine following epidural bolus and infusion in neonates and young infants. Secondary aims were to investigate the influence of alpha-1-acid glycoprotein (AAG) on the concentrationtime profiles and to determine the efficacy and adverse event profile of the epidural regimen. Thirty-one infants aged 40-63 weeks of postmenstrual age (PMA) undergoing hernia repair or abdominal surgery received an epidural injection of 1.5 mg kg(-1) bupivacaine (0.25%) or ropivacaine (0.2%) followed 2 h later by an infusion of 0.2 mg kg(-1) h(-1) in those undergoing abdominal surgery. Total and unbound concentrations of bupivacaine and ropivacaine were analyzed using NONMEM. Hourly pain scores and adverse effects were recorded. Results: Bupivacaine data were available from 11 infants (five had infusions) and ropivacaine from 13 infants (four had infusions). Alpha-1-acid glycoprotein and total bupivacaine and ropivacaine concentrations accumulated during infusions, but unbound concentrations did not. Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg l(-1) (bupivacaine) and 0.13 mg l(-1) (ropivacaine). Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l h(-1) kg) 1 and of total (unbound) ropivacaine were 0.288 (3.31) l h(-1) kg(-1). Pain scores requiring pain team referral occurred once with bupivacaine and four times with ropivacaine. No toxicity was observed. Epidural infusions of 0.2 mg(-1) kg(-1) h(-1) bupivacaine or ropivacaine appeared to be well tolerated and efficacious in this population. No accumulation of unbound drug concentrations occurred.

KW - epidural bupivacaine

KW - ropivacaine

KW - young infants

KW - pharmacokinetic profiles

UR - http://www.scopus.com/inward/record.url?scp=84859616599&partnerID=8YFLogxK

U2 - 10.1111/j.1460-9592.2011.03771.x

DO - 10.1111/j.1460-9592.2011.03771.x

M3 - Article

VL - 22

SP - 430

EP - 437

JO - Pediatric Anesthesia

T2 - Pediatric Anesthesia

JF - Pediatric Anesthesia

SN - 1155-5645

IS - 5

ER -